FDA Approved: JARDIANCE — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for JARDIANCE (empagliflozin) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

SUPPL AP for JARDIANCE (EMPAGLIFLOZIN)